Janux Therapeutics

Janux Therapeutics develops tumour-activated T-cell engagers using its TRACTr (T cell engager) and TRACIr (co-stimulatory) platforms, plus the ARM platform for autoimmune disease. JANX007 is a PSMA-TRACTr in a phase 1b trial in metastatic castration-resistant prostate cancer, with dose optimisation in taxane-naive patients and an expansion cohort combining it with darolutamide. JANX014, a double-masked PSMA-TRACTr, is in phase 1 in the same setting, and JANX013, a PSMA-targeted CD28 co-stimulatory TRACIr, is expected to enter the clinic in the second half of 2026. JANX011 (CD19-ARM) is in a phase 1 healthy volunteer study for autoimmune disease. Janux listed on Nasdaq in June 2021, raising about $223 million, and reported $970.9 million in cash and short-term investments at 30 June 2026.